Chronic kidney disease and coenzyme Q10 supplementation

Hargreaves, Iain P.; Mantle, David; Milford, David V.

doi:10.12968/jokc.2019.4.2.82

Cited by 9 publications

(10 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased levels of total antioxidant capacity in diabetic hemodialyzed patients after CoQ 10 supplementation were documented (41). In agreement with others, we suppose that CoQ 10 supplementation could be important for improving the kidney function, and that clinical monitoring of platelet mitochondrial function, and plasma and platelet CoQ 10 levels could be important for determining the dosage of CoQ 10 supplementation (42,43,44,45,46,47).…”

Section: Plasma Coq 10-total In Subgroups Of Ckd Patients With Concomsupporting

confidence: 90%

The importance of coenzyme Q10 and its ratio to cholesterol in the progress of chronic kidney diseases linked to non- -communicable diseases

Gvozdjáková¹,

Kucharská²,

Sumbalová³

et al. 2020

BLL

View full text Add to dashboard Cite

OBJECTIVES: The mortality of patients with chronic kidney diseases (CKD) increases with the decrease in glomerular fi ltration rate (eGFR). In the progress of CKD that is closely linked to non-communicable diseases (NCDs), the role of coenzyme Q 10 (CoQ 10) is not fully evaluated. We aimed to evaluate the importance of CoQ 10, CoQ 10 /cholesterol ratio, and oxidative stress in the progress of CKD. PATIENTS AND METHODS: The control group was constituted of 19 healthy subjects who volunteered to enrol in the study, CKD group consisted of 58 patients with CKD, of whom 54 had CKD combined with hypertension, 22 had CKD combined with hypertension and diabetes type 2 , and 18 had CKD combined with hypertension and statin therapy. We observed age, BMI, creatinine, uric acid, eGFR, hemoglobin, CRP, glucose, lipids fraction, and liver enzymes. Coenzyme Q 10-TOTAL (ubiquinol+ubiquinone) in platelets and plasma were determined using HPLC method with UV detection. Indexed of CoQ 10 /lipid fractions were evaluated. Oxidative stress was determined as thiobarbituric acid-reactive substances (TBARS). RESULTS: With increased stages of CKD, eGFR and CoQ 10 as well as its ratio to lipids were signifi cantly reduced while TBARS increased. CONCLUSION: We assume that lower endogenous CoQ 10 level may be one of the reasons of kidney dysfunction. CoQ 10 /lipids ratio and increase in oxidative stress can predict the progression of CKD in patients with arterial hypertension, diabetes mellitus and dyslipidemia (Tab. 2, Fig. 4, Ref. 49). Text in PDF www.elis.sk KEY WORDS: chronic kidney disease, non-communicable diseases, glomerular fi ltration, creatinine, coenzyme Q 10, oxidative stress, index of CoQ 10-TOTAL /lipids.

show abstract

Section: Plasma Coq 10-total In Subgroups Of Ckd Patients With Concomsupporting

confidence: 90%

The importance of coenzyme Q10 and its ratio to cholesterol in the progress of chronic kidney diseases linked to non- -communicable diseases

Gvozdjáková¹,

Kucharská²,

Sumbalová³

et al. 2020

BLL

View full text Add to dashboard Cite

show abstract

“…Chronic inflammation, oxidative stress, and changes in cellular energy metabolism participate in reduced kidney function [11][12][13]. Mitochondrial dysfunction and reduced CoQ 10 concentration contribute to dysfunctional platelet activity in diseases, such as neurological diseases, cardiovascular diseases, diabetes mellitus, sepsis, Alzheimer's disease, Parkinson's disease, and chronic kidney disease [5,[14][15][16][17].…”

Section: Discussionmentioning

confidence: 99%

“…As an antioxidant, CoQ 10 quenches free radicals and directly prevents lipid peroxidation [9]. Different studies have demonstrated that platelet mitochondrial dysfunction has also been used for studying mitochondria-related diseases [10][11][12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Platelet Mitochondrial Respiration, Endogenous Coenzyme Q10 and Oxidative Stress in Patients with Chronic Kidney Disease

et al. 2020

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is characterized by a progressive loss of renal function and a decrease of glomerular filtration rate. Reduced mitochondrial function, coenzyme Q10 (CoQ10), and increased oxidative stress in patients with CKD contribute to the disease progression. We tested whether CoQ10 levels, oxidative stress and platelet mitochondrial bioenergetic function differ between groups of CKD patients. Methods: Twenty-seven CKD patients were enrolled in this trial, 17 patients had arterial hypertension (AH) and 10 patients had arterial hypertension and diabetes mellitus (AH and DM). The control group consisted of 12 volunteers. A high-resolution respirometry (HRR) method was used for the analysis of mitochondrial bioenergetics in platelets, and an HPLC method with UV detection was used for CoQ10 determination in platelets, blood, and plasma. Oxidative stress was determined as thiobarbituric acid reactive substances (TBARS). Results: Platelets mitochondrial respiration showed slight, not significant differences between the groups of CKD patients and control subjects. The oxygen consumption by intact platelets positively correlated with the concentration of CoQ10 in the platelets of CKD patients. Conclusion: A decreased concentration of CoQ10 and oxidative stress could contribute to the progression of renal dysfunction in CKD patients. The parameters of platelet respiration assessed by high-resolution respirometry can be used only as a weak biological marker for mitochondrial diagnosis and therapy monitoring in CKD patients.

show abstract

“…Examples of secondary CoQ10 deficiency resulting from such genes include mutations in the APTX gene encoding the protein aprataxin in ataxia oculomotor aprataxin 1 disorder [ 37 ], and the BRAF gene encoding the enzyme serine/threonine-protein kinase B-Raf in cardiofaciocutaneous syndrome [ 38 ], multiple acyl-CoA dehydrogenase deficiency (by mutations in the ETFDH gene; [ 39 ]) and spinocerebellar ataxia-10 (by mutations in the AN010 gene; [ 40 ]). In addition, secondary CoQ10 deficiencies associated with a number of disorders have been reported, including primary METC disease and mitochondrial DNA depletion syndrome [ 41 , 42 ], cardiovascular disease [ 43 ], chronic kidney disease [ 44 ], type II diabetes [ 45 ] and metabolic syndrome [ 46 ]. Recently, evidence of a plasma CoQ10 deficiency has been reported in the lysosomal storage disorder mucopolysaccharidosis (MPS), as well the metabolic disease phenylketonuria (PKU) [ 47 ].…”

Section: Deficiency Of Coq10mentioning

confidence: 99%

“…Secondary deficiencies of CoQ10 typically occur in the mitochondrial myopathies [ 41 , 49 ], cardiovascular disease [ 57 ], type II diabetes [ 45 ], chronic kidney disease [ 44 ], liver disease [ 43 ] and critical illness [ 43 ]. Depletion of CoQ10 in these disorders may compromise cellular antioxidant status and result in impaired mitochondrial function and cellular energy supply, resulting in, for example, heart failure.…”

Section: Clinical Consequences Of a Coq10 Deficiencymentioning

confidence: 99%

Disorders of Human Coenzyme Q10 Metabolism: An Overview

Hargreaves

Heaton

Mantle

2020

IJMS

Self Cite

104

View full text Add to dashboard Cite

Coenzyme Q10 (CoQ10) has a number of vital functions in all cells, both mitochondrial and extramitochondrial. In addition to its key role in mitochondrial oxidative phosphorylation, CoQ10 serves as a lipid soluble antioxidant, plays an important role in fatty acid, pyrimidine and lysosomal metabolism, as well as directly mediating the expression of a number of genes, including those involved in inflammation. In view of the central role of CoQ10 in cellular metabolism, it is unsurprising that a CoQ10 deficiency is linked to the pathogenesis of a range of disorders. CoQ10 deficiency is broadly classified into primary or secondary deficiencies. Primary deficiencies result from genetic defects in the multi-step biochemical pathway of CoQ10 synthesis, whereas secondary deficiencies can occur as result of other diseases or certain pharmacotherapies. In this article we have reviewed the clinical consequences of primary and secondary CoQ10 deficiencies, as well as providing some examples of the successful use of CoQ10 supplementation in the treatment of disease.

show abstract

Chronic kidney disease and coenzyme Q10 supplementation

Abstract: The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

Cited by 9 publications

References 86 publications

The importance of coenzyme Q10 and its ratio to cholesterol in the progress of chronic kidney diseases linked to non- -communicable diseases

The importance of coenzyme Q10 and its ratio to cholesterol in the progress of chronic kidney diseases linked to non- -communicable diseases

Platelet Mitochondrial Respiration, Endogenous Coenzyme Q10 and Oxidative Stress in Patients with Chronic Kidney Disease

Disorders of Human Coenzyme Q10 Metabolism: An Overview

Contact Info

Product

Resources

About